ClinicalEton Pharma gets FDA nod on Rezipres® for treatment...

Eton Pharma gets FDA nod on Rezipres® for treatment of hypotension in anesthesia settings

-

Rezipres, an ephedrine HCL (hydrochloride) injectable manufactured by Eton Pharmaceuticals, has been approved by FDA to treat clinically significant hypotension ( low blood pressure) observed in anesthetic locations. Eton’s stock trading remains suspended.
“This innovative sulfite-free formulation has been successfully sold in Europe for years, and we are excited to make it available to U.S. patients shortly,” stated Sean Brynjelsen, CEO of the company.
The investigational medication is under the evaluation of the FDA with a deadline of June 18 specified under PDUFA (Prescription Drug User Fee Act).

Topiramate oral solution, which has a deadline of August 6 set under the Prescription Drug User Fee Act, has also been submitted to get marketing authorization.

Life Sciences Voice Logo mobile
+ posts

Latest news

The Rise of AI-Native Biotech Companies

Executive Summary Artificial intelligence is reshaping nearly every aspect of the life sciences industry. Most pharmaceutical and biotechnology companies are integrating...

Why Every Pharma Company Is Becoming a Technology Company

Executive Summary For much of its history, the pharmaceutical industry has been defined by scientific discovery. Competitive advantage depended on breakthrough...

Novartis Set to Buy UK Biotech Myricx For Over $1.1B

Novartis is expanding its presence in the antibody-drug conjugate (ADC) field by agreeing to acquire Myricx Bio in a...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you